People

Gregory Karczmar, PhD

  • Professor of Radiology
    Committee on Medical Physics
  • Research and Scholarly Interests: Breast cancer screening with MRI, Community outreach, Prostate cancer screening with MRI, Quantitative MRI, Screening iof underserved groups
  • Websites: Research Network Profile
  • Contact: gskarczm@uchicago.edu
  • Graduate Program: Medical Physics

I have developed new approaches to functional and anatomic magnetic resonance imaging for over 30 years. I’ve applied these methods to improve detection and accurate diagnosis of cancer, and monitor cancer response to therapy. I am the Director of Magnetic Resonance Imaging Research at the University of Chicago, and Co-Director of the Advanced Imaging Program of the University of Chicago Comprehensive Cancer center. I’ve collaborated with our outstanding mammographic group and medical physics colleagues for many years to build internationally recognized research program in quantitative breast cancer MR imaging – which parallels and compliments a leading clinical program in breast cancer diagnosis and management. Similarly, I’ve collaborated with Dr. Oto and others to develop a leading translational research program focused on improving prostate cancer screening with MRI, and using MRI to guide therapye. With these collaborators, I’ve made pioneering contributions to MRI methods that improve prostate and breast cancer diagnosis and treatment. My research includes use of pre-clinical methods for breast and prostate cancer to improve understanding of cancer biology and guide the development of improved clinical methods.

University of California at Berkeley
Berkeley, CA
Ph.D. - Physical Chemistry
1984

Reed College
Portland
B.A - Physical Chemistry
1977

Differences Between Ipsilateral and Contralateral Early Parenchymal Enhancement Kinetics Predict Response of Breast Cancer to Neoadjuvant Therapy.
Ren Z, Pineda FD, Howard FM, Hill E, Szasz T, Safi R, Medved M, Nanda R, Yankeelov TE, Abe H, Karczmar GS. Differences Between Ipsilateral and Contralateral Early Parenchymal Enhancement Kinetics Predict Response of Breast Cancer to Neoadjuvant Therapy. Acad Radiol. 2022 Mar 26.
PMID: 35351365

Histological validation of prostate tissue composition measurement using hybrid multi-dimensional MRI: agreement with pathologists' measures.
Chatterjee A, Antic T, Gallan AJ, Paner GP, Lin LI, Karczmar GS, Oto A. Histological validation of prostate tissue composition measurement using hybrid multi-dimensional MRI: agreement with pathologists' measures. Abdom Radiol (NY). 2022 02; 47(2):801-813.
PMID: 34878579

Validation of Prostate Tissue Composition by Using Hybrid Multidimensional MRI: Correlation with Histologic Findings.
Chatterjee A, Mercado C, Bourne RM, Yousuf A, Hess B, Antic T, Eggener S, Oto A, Karczmar GS. Validation of Prostate Tissue Composition by Using Hybrid Multidimensional MRI: Correlation with Histologic Findings. Radiology. 2022 02; 302(2):368-377.
PMID: 34751615

Enhancement-constrained acceleration: A robust reconstruction framework in breast DCE-MRI.
Easley TO, Ren Z, Kim B, Karczmar GS, Barber RF, Pineda FD. Enhancement-constrained acceleration: A robust reconstruction framework in breast DCE-MRI. PLoS One. 2021; 16(10):e0258621.
PMID: 34710110

Can Pre-treatment Quantitative Multi-parametric MRI Predict the Outcome of Radiotherapy in Patients with Prostate Cancer?
Chatterjee A, Turchan WT, Fan X, Griffin A, Yousuf A, Karczmar GS, Liauw SL, Oto A. Can Pre-treatment Quantitative Multi-parametric MRI Predict the Outcome of Radiotherapy in Patients with Prostate Cancer? Acad Radiol. 2021 Oct 10.
PMID: 34645572

Effectiveness of Dynamic Contrast Enhanced MRI with a Split Dose of Gadoterate Meglumine for Detection of Prostate Cancer.
Fan X, Chatterjee A, Pittman JM, Yousuf A, Antic T, Karczmar GS, Oto A. Effectiveness of Dynamic Contrast Enhanced MRI with a Split Dose of Gadoterate Meglumine for Detection of Prostate Cancer. Acad Radiol. 2021 Sep 25.
PMID: 34583866

An in silico validation framework for quantitative DCE-MRI techniques based on a dynamic digital phantom.
Wu C, Hormuth DA, Easley T, Eijkhout V, Pineda F, Karczmar GS, Yankeelov TE. An in silico validation framework for quantitative DCE-MRI techniques based on a dynamic digital phantom. Med Image Anal. 2021 10; 73:102186.
PMID: 34329903

Robustness of radiomic features of benign breast lesions and hormone receptor positive/HER2-negative cancers across DCE-MR magnet strengths.
Whitney HM, Drukker K, Edwards A, Papaioannou J, Medved M, Karczmar G, Giger ML. Robustness of radiomic features of benign breast lesions and hormone receptor positive/HER2-negative cancers across DCE-MR magnet strengths. Magn Reson Imaging. 2021 10; 82:111-121.
PMID: 34174331

High spectral and spatial resolution MRI of prostate cancer: a pilot study.
Medved M, Chatterjee A, Devaraj A, Harmath C, Lee G, Yousuf A, Antic T, Oto A, Karczmar GS. High spectral and spatial resolution MRI of prostate cancer: a pilot study. Magn Reson Med. 2021 09; 86(3):1505-1513.
PMID: 33963782

Improving Tumor Hypoxia Location in 18F-Misonidazole PET with Dynamic Contrast-enhanced MRI Using Quantitative Electron Paramagnetic Resonance Partial Oxygen Pressure Images.
Gertsenshteyn I, Epel B, Barth E, Leoni L, Markiewicz E, Tsai HM, Fan X, Giurcanu M, Bodero D, Zamora M, Sundramoorthy S, Kim H, Freifelder R, Bhuiyan M, Kucharski A, Karczmar G, Kao CM, Halpern H, Chen CT. Improving Tumor Hypoxia Location in 18F-Misonidazole PET with Dynamic Contrast-enhanced MRI Using Quantitative Electron Paramagnetic Resonance Partial Oxygen Pressure Images. Radiol Imaging Cancer. 2021 03; 3(2):e200104.
PMID: 33817651

View All Publications